157 related articles for article (PubMed ID: 7865870)
1. The involvement of taurine in the action mechanism of sodium valproate (VPA) in the treatment of epilepsy.
Anyanwu E; Harding GF
Acta Physiol Pharmacol Ther Latinoam; 1993; 43(1-2):20-7. PubMed ID: 7865870
[TBL] [Abstract][Full Text] [Related]
2. Furosemide potentiates the anticonvulsant action of valproate in the mouse maximal electroshock seizure model.
Luszczki JJ; Sawicka KM; Kozinska J; Borowicz KK; Czuczwar SJ
Epilepsy Res; 2007 Aug; 76(1):66-72. PubMed ID: 17659862
[TBL] [Abstract][Full Text] [Related]
3. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
4. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
Dutta S; Faught E; Limdi NA
J Clin Pharm Ther; 2007 Aug; 32(4):365-71. PubMed ID: 17635338
[TBL] [Abstract][Full Text] [Related]
5. Structure-function studies for the panacea, valproic acid.
Terbach N; Williams RS
Biochem Soc Trans; 2009 Oct; 37(Pt 5):1126-32. PubMed ID: 19754465
[TBL] [Abstract][Full Text] [Related]
6. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers.
Watson DG; Watterson JM; Lenox RH
J Pharmacol Exp Ther; 1998 Apr; 285(1):307-16. PubMed ID: 9536026
[TBL] [Abstract][Full Text] [Related]
7. Valproate in the treatment of epilepsy in people with intellectual disability.
Friis ML
J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():32-5. PubMed ID: 10030429
[TBL] [Abstract][Full Text] [Related]
8. Transient decrease in serum albumin concentrations in epileptic children treated with sodium valproate monotherapy.
Attilakos A; Voudris KA; Katsarou E; Prassouli A; Mastroyianni S; Garoufi A
Clin Neuropharmacol; 2007; 30(3):145-9. PubMed ID: 17545749
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
[TBL] [Abstract][Full Text] [Related]
10. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
McCabe PH; Michel NC; McNew CD; Lehman EB
Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766
[TBL] [Abstract][Full Text] [Related]
11. Excitability of the human epileptic cortex after chronic valproate: a reappraisal.
Cantello R; Civardi C; Varrasi C; Vicentini R; Cecchin M; Boccagni C; Monaco F
Brain Res; 2006 Jul; 1099(1):160-6. PubMed ID: 16774745
[TBL] [Abstract][Full Text] [Related]
12. Thyroid function in children with epilepsy treated with sodium valproate monotherapy: a prospective study.
Attilakos A; Katsarou E; Prassouli A; Mastroyianni S; Voudris K; Fotinou A; Garoufi A
Clin Neuropharmacol; 2009; 32(1):32-4. PubMed ID: 18978499
[TBL] [Abstract][Full Text] [Related]
13. Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate.
Della Paschoa OE; Voskuyl RA; Danhof M
Br J Pharmacol; 1998 Dec; 125(7):1610-6. PubMed ID: 9884091
[TBL] [Abstract][Full Text] [Related]
14. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
Löscher W
CNS Drugs; 2002; 16(10):669-94. PubMed ID: 12269861
[TBL] [Abstract][Full Text] [Related]
15. Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.
Luszczki JJ; Czuczwar P; Cioczek-Czuczwar A; Czuczwar SJ
Eur J Pharmacol; 2006 Oct; 547(1-3):65-74. PubMed ID: 16930590
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of antiepileptic and antimyoclonic drugs.
Pranzatelli MR; Nadi NS
Adv Neurol; 1995; 67():329-60. PubMed ID: 8848979
[TBL] [Abstract][Full Text] [Related]
17. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
Hoffmann K; Czapp M; Löscher W
Epilepsy Res; 2008 Oct; 81(2-3):107-13. PubMed ID: 18538545
[TBL] [Abstract][Full Text] [Related]
18. Effects of valproate, vigabatrin and tiagabine on GABA uptake into human astrocytes cultured from foetal and adult brain tissue.
Fraser CM; Sills GJ; Butler E; Thompson GG; Lindsay K; Duncan R; Howatson A; Brodie MJ
Epileptic Disord; 1999 Sep; 1(3):153-7. PubMed ID: 10937147
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
Epilepsia; 2006 Nov; 47(11):1841-54. PubMed ID: 17116023
[TBL] [Abstract][Full Text] [Related]
20. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children.
Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Karall D; Schoenherr E; Tatarczyk T; Engl J; Laimer M; Luef G; Ebenbichler CF
Epilepsy Res; 2008 Aug; 80(2-3):142-9. PubMed ID: 18472247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
